2-(Ethylamino)-1,2-diphenylethanone

2-(Ethylamino)-1,2-diphenylethanone
Clinical data
ATC code	None;
Identifiers
	IUPAC name 2-(ethylamino)-1,2-diphenylethanone;
CAS Number	22312-16-9 ;
PubChem CID	69702363;
ChemSpider	129327880;
UNII	8R3EAH84GZ;
CompTox Dashboard (EPA)	DTXSID401337074 ;
Chemical and physical data
Formula	C16H17NO
Molar mass	239.318 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2;
	InChI InChI=1S/C16H17NO/c1-2-17-15(13-9-5-3-6-10-13)16(18)14-11-7-4-8-12-14/h3-12,15,17H,2H2,1H3; Key:NHNVMSYWZNJBOO-UHFFFAOYSA-N;

2-(Ethylamino)-1,2-diphenylethanone (also known as α-ethylamino-deoxybenzoin, [α-(Ethylamino)benzyl]-(phenyl)-ketone and βk-Ephenidine) is a chemical compound which was first invented in 1955,^[1] researched by ICI in 1969 as an antidepressant,^[2] and subsequently claimed by AstraZeneca as an inhibitor of the enzyme 11β-Hydroxysteroid dehydrogenase type 1.^[3] No other pharmacological data has been disclosed, though its chemical structure closely resembles that of certain designer drug compounds such as ephenidine and N-ethylhexedrone.

References

↑ Hinderling R, Prijs B, Erlenmeyer H (1955). "Über α-Alkylamino-ketone". Helvetica Chimica Acta. 38 (6): 1415–1420. doi:10.1002/hlca.19550380613.
↑ GB 1143263, Gilman DJ, "Desyl amines and compositions thereof. gdate = 19 February 1969", assigned to ICI Ltd.
↑ US Abandoned 2005272036, Barton P, Clarke D, Davies C, Hargreaves R, Pease J, Rankine M, "Ketones", published 8 December 2005, assigned to AstraZeneca AB

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[1] Hinderling R, Prijs B, Erlenmeyer H (1955). "Über α-Alkylamino-ketone". Helvetica Chimica Acta. 38 (6): 1415–1420. doi:10.1002/hlca.19550380613.

[2] GB 1143263, Gilman DJ, "Desyl amines and compositions thereof. gdate = 19 February 1969", assigned to ICI Ltd.

[3] US Abandoned 2005272036, Barton P, Clarke D, Davies C, Hargreaves R, Pease J, Rankine M, "Ketones", published 8 December 2005, assigned to AstraZeneca AB

[1]

[2]

[3]

This page was redesigned at the edge.

2-(Ethylamino)-1,2-diphenylethanone

See also

References